Teva Pharmaceutical Industries (TEVA) Net Cash Flow (2016 - 2025)
Historic Net Cash Flow for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $1.4 billion.
- Teva Pharmaceutical Industries' Net Cash Flow rose 122330.1% to $1.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $235.0 million, marking a year-over-year decrease of 524.19%. This contributed to the annual value of $235.0 million for FY2025, which is 524.19% down from last year.
- According to the latest figures from Q4 2025, Teva Pharmaceutical Industries' Net Cash Flow is $1.4 billion, which was up 122330.1% from $51.0 million recorded in Q3 2025.
- In the past 5 years, Teva Pharmaceutical Industries' Net Cash Flow registered a high of $1.4 billion during Q4 2025, and its lowest value of -$1.6 billion during Q1 2025.
- Moreover, its 5-year median value for Net Cash Flow was $108.5 million (2022), whereas its average is $90.7 million.
- As far as peak fluctuations go, Teva Pharmaceutical Industries' Net Cash Flow soared by 168611.11% in 2023, and later plummeted by 115801.53% in 2025.
- Teva Pharmaceutical Industries' Net Cash Flow (Quarter) stood at $201.0 million in 2021, then skyrocketed by 113.93% to $430.0 million in 2022, then skyrocketed by 111.4% to $909.0 million in 2023, then plummeted by 88.67% to $103.0 million in 2024, then skyrocketed by 1223.3% to $1.4 billion in 2025.
- Its Net Cash Flow stands at $1.4 billion for Q4 2025, versus $51.0 million for Q3 2025 and $469.0 million for Q2 2025.